Related Experiment Video
Updated: Apr 21, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document
Barth Wilsey1, J Hampton Atkinson, Thomas D Marcotte
1*Department of Physical Medicine & Rehabilitation, VA Northern California Health Care System †Department of Physical Medicine and Rehabilitation, University of California Davis Medical Center, Sacramento ‡VA San Diego Health Care System §Department of Psychiatry, University of California, San Diego, La Jolla, CA.
Aim:
Pain practitioners would seem to have an obligation to understand and inform their patients on key issues of the evidence base on cannabinoid therapeutics. One way to fulfill this obligation might be to borrow from concepts developed in the prescription of opioids: the use of a written agreement to describe and minimize risks. Regrettably, the widespread adoption of opioids was undertaken while harmful effects were minimized; obviously, no one wants to repeat this misstep.
Objective:
This article describes a method of educating patients in a manner analogous to other treatment agreements.
Background:
Surveys have demonstrated that pain is the most common indication for medical use of cannabis. As more individuals gain access to this botanical product through state ballot initiatives and legislative mandate, the pain specialist is likely to be confronted by patients either seeking such treatment where permitted, or otherwise inquiring about its potential benefits and harms, and alternative pharmaceuticals containing cannabinoids.
Methods:
PubMed searches were conducted using the following keywords: cannabis guidelines, harmful effects of cannabis, medical marijuana, medicinal cannabis, opioid cannabis interaction, cannabis dependence and cannabis abuse
Results:
: The authors selected individual tenets a medicinal cannabis patient would be asked to review and acknowledge via signature.
Conclusions:
Undoubtedly, the knowledge base concerning risks will be an iterative process as we learn more about the long-term use of medicinal cannabis. But we should start the process now so that patients may be instructed about our current conception of what the use of medicinal cannabis entails.
Related Concept Videos
Analgesia and Pain Management
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Documentation in Long-Term and Home Healthcare Setting
Long-Term Care Facilities
Treatment Resistant Cancers
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

